NASDAQ
1.35USD
+0.10 (+8.00%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
17.3M
P/E
—
EPS
—
Beta
0.80
52W range
0.555-1.3772
Day range
1.26–1.38
Open
1.27
Prev close
1.25
Volume
375.5K
Avg volume
265.9K
Dividend
0.00
IPO
2021-10-29
https://www.globenewswire.com/news-release/2026/08/13/3344531/0/en/biofrontera-inc-reports-strong-second-quarter-2026-financial-results-driven-by-33-revenue-growth.html · 8/13/2026+0.80
https://www.defenseworld.net/2026/03/21/biofrontera-q4-earnings-call-highlights.html · 3/21/2026+1.00
https://www.zacks.com/stock/news/2882252/are-medical-stocks-lagging-align-technology-algn-this-year?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_1-2882252 · 3/11/2026+0.90
https://www.zacks.com/stock/news/2881060/biofrontera-inc-bfri-upgraded-to-buy-here-s-why?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2881060 · 3/9/2026+1.00
https://www.globenewswire.com/news-release/2026/02/09/3234622/0/en/Biofrontera-Announces-Positive-Results-in-Phase-3-Study-of-Ameluz-PDT-for-Actinic-Keratoses-on-the-Extremities-Neck-and-Trunk-Meeting-Primary-Endpoint.html · 2/9/2026+1.00
https://www.defenseworld.net/2026/01/17/biofrontera-conference-ameluz-growth-plan-80-margin-outlook-and-fda-catalysts-in-focus.html · 1/17/2026+0.60
https://www.globenewswire.com/news-release/2026/01/08/3215399/0/en/Biofrontera-Inc-Announces-Data-Base-Locks-for-Two-Clinical-Studies-Supporting-Key-Data-and-Regulatory-Milestones.html · 1/8/2026+0.60
https://seekingalpha.com/article/4843232-biofrontera-inc-bfri-q3-2025-earnings-call-transcript · 11/13/2025+0.00
https://www.globenewswire.com/news-release/2025/11/06/3183042/0/en/Biofrontera-Inc-to-Report-Third-Quarter-2025-Financial-Results-on-November-12-2025-and-Host-a-Conference-Call-on-November-13-2025.html · 11/6/2025+0.00
https://www.globenewswire.com/news-release/2025/09/23/3154820/0/en/Biofrontera-Inc-Engages-Lytham-Partners-to-Lead-Strategic-Investor-Relations-and-Shareholder-Communication-Program.html · 9/23/2025+0.60
https://seekingalpha.com/article/4813707-biofrontera-inc-bfri-q2-2025-earnings-conference-call-transcript · 8/14/2025+0.00
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
